These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16081580)

  • 1. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M; Zhang PL; Pellitteri PK; Law A; Kennedy TL; Brown RE
    Ann Clin Lab Sci; 2005; 35(3):251-8. PubMed ID: 16081580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Lun M; Zhang PL; Siegelmann-Danieli N; Blasick TM; Brown RE
    Ann Clin Lab Sci; 2005; 35(1):15-24. PubMed ID: 15830705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
    Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
    Kamer S; Ren Q; Dicker AP
    Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A; Zeng Q; Wang CY
    Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma.
    Jackson-Bernitsas DG; Ichikawa H; Takada Y; Myers JN; Lin XL; Darnay BG; Chaturvedi MM; Aggarwal BB
    Oncogene; 2007 Mar; 26(10):1385-97. PubMed ID: 16953224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nuclear factor-κB activity by small interfering RNA in esophageal squamous cell carcinoma cell lines.
    Hatata T; Higaki K; Nanba E; Tatebe S; Ikeguchi M
    Oncol Rep; 2011 Sep; 26(3):659-64. PubMed ID: 21617867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice.
    Tian F; Zhang C; Tian W; Jiang Y; Zhang X
    Oncol Rep; 2012 Jul; 28(1):232-40. PubMed ID: 22552693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.
    Allen CT; Ricker JL; Chen Z; Van Waes C
    Head Neck; 2007 Oct; 29(10):959-71. PubMed ID: 17405170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
    Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
    Macha MA; Matta A; Chauhan SS; Siu KW; Ralhan R
    Carcinogenesis; 2011 Mar; 32(3):368-80. PubMed ID: 21177768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
    Ito K; Kobayashi M; Kuroki S; Sasaki Y; Iwata T; Mori K; Kuroki T; Ozawa Y; Tetsuka M; Nakagawa T; Hiroi T; Yamamoto H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Dec; 198(3):577-82. PubMed ID: 24035468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
    Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Knecht R; Hambek M
    Anticancer Res; 2008; 28(4B):2239-43. PubMed ID: 18751401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
    Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo.
    Duffey DC; Chen Z; Dong G; Ondrey FG; Wolf JS; Brown K; Siebenlist U; Van Waes C
    Cancer Res; 1999 Jul; 59(14):3468-74. PubMed ID: 10416612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.